Myriad Genetics (MYGN) Capital Expenditures (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Capital Expenditures data on file, last reported at $5.4 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $5.4 million, up 1.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.7 million (down 10.8% YoY), and the FY2025 annual result was $15.6 million, down 17.89% from the prior year.
• Capital Expenditures advanced to $5.4 million in Q1 2026 per MYGN's latest filing, from $4.7 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $56.6 million in Q4 2023 and troughed at -$35.7 million in Q3 2023.
• A 5-year average of $8.7 million and a median of $5.3 million in 2025 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 1232.35% in 2022 and fell as far as 533.33% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $45.3 million in 2022, then rose by 24.94% to $56.6 million in 2023, then sank by 93.64% to $3.6 million in 2024, then soared by 30.56% to $4.7 million in 2025, then increased by 14.89% to $5.4 million in 2026.
• Business Quant data shows MYGN's Capital Expenditures at $5.4 million in Q1 2026, $4.7 million in Q4 2025, and $2.8 million in Q3 2025.